Irving Ling

Irving Ling is a seasoned professional in the field of translational medicine and immunology, currently serving as the AVP and Head of Translational Medicine Immunology at Merck since February 2025. Ling has also been a mentor for early-stage startups at Nucleate since April 2020. Prior experience includes roles as Executive Medical Director and various director-level positions in immunology translational medicine at Johnson & Johnson Innovative Medicine from May 2021 to February 2025, and as Associate Scientific Director at Takeda from June 2019 to May 2021. Ling began a postdoctoral position at the MRC Weatherall Institute of Molecular Medicine from August 2016 to August 2019, focusing on epigenetic regulation in genome biology. Educational qualifications include a NIHR Postdoctoral Fellowship from the University of Oxford and a Master's degree in healthcare management from Harvard T.H. Chan School of Public Health.